Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world use of once-weekly semaglutide in Thai patients with type 2 diabetes mellitus
TCTR20211014001Not yet recruiting
- Sponsor
- Theptarin Hospital
- Start
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Theptarin Hospital. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on TCTR20211014001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20211014001.